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Abstract
Objective: To compare serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 between 
female patients with recurrent major depressive disorder (MDD) and healthy controls, verifying 
if there is a difference in the levels of these mediators between those with or without current 
suicidal ideation. Methods: Thirty female outpatients with recurrent MDD were divided in two 
groups accordingly the presence or absence of suicidal ideation. These groups were compared 
with 16 healthy controls. Serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 were 
determined. Depression severity was evaluated by Beck Depression Inventory (BDI). Suicidal 
ideation was assessed by SCID-I and BDI. Results: Patients with recurrent MDD and healthy 
controls did not differ in age, socioeconomic status, and education. All patients reported high 
scores of BDI (mean, SD, n; 29.75, 10.55, 28). Multivariable analysis of covariance adjusted for 
age and BMI showed that MDD patients with suicidal ideation presented lower levels of MCP-1/
CCL2 and RANTES/CCL5 (p < 0.001) and higher levels of Eotaxin/CCL11 (p = 0.04) compared to 
healthy controls. These differences remained significant after adjusting for depression severity. 
Conclusion: The findings of this study indicated that the presence of recurrent MDD with suicidal 
ideation is associated with differences in inflammatory chemokines when compared to those 
without suicidal ideation.
©2012 Elsevier Editora Ltda. 
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Níveis periféricos de quimiocina em mulheres com depressão maior com ideação 
suicida
RESUMO
Objetivo: Comparar os níveis séricos de MCP-1/CCL2, RANTES/CCL5 e Eotaxin/CCL11 entre 
pacientes do sexo feminino com transtorno depressivo maior (TDM) recorrente e controles 
saudáveis , verificando se há diferença nos níveis desses mediadores entre os indivíduos com ou 
sem ideação suicida. Métodos: Trinta pacientes do sexo feminino com TDM recorrente foram 
divididas em dois grupos de acordo com a presença ou ausência de ideação suicida. Esses grupos 
foram comparados com 16 controles saudáveis. Os níveis séricos de MCP-1/CCL2, RANTES/CCL5 
e Eotaxin/CCL11 foram determinados. A gravidade da depressão foi avaliada usando o Beck 
Depression Inventory (BDI) e a ideação suicida foi avaliada usando o SCID-I e o BDI. Resultados: 
As pacientes com TDM recorrente e os controles saudáveis não diferiram em idade, status 
socioeconômico e educação. Todas as pacientes relataram altas pontuações no BDI (média, SD, 
n; 29,75, 10,55, 28). A análise de covariância multivariada ajustada para idade e de IMC mostrou 
que as pacientes com TDM e ideação suicida apresentaram níveis mais baixos de MCP-1/CCL2 e 
RANTES/CCL5 (p < 0,001) e níveis mais elevados de Eotaxin/CCL11 (p = 0,04) em comparação 
com os controles saudáveis. Essas diferenças permaneceram significantes após o ajuste para 
gravidade da depressão. Conclusão: Os resultados deste estudo indicaram que a presença de 
TDM recorrente com ideação suicida está associada a diferenças nas quimiocinas inflamatórias 
na comparação com os indivíduos sem ideação suicida.
©2012 Elsevier Editora Ltda. Todos os direitos reservados.
DESCRITORES:
Suicídio;
Ideação suicida;
Quimiocinas;
Citocinas;
Transtorno Depressivo 
Maior; 
Transtornos do Humor;
Inflamação;
Imunidade. 
Introduction
Suicide is a major problem in public health, with approxi-
mately 1 million people dying from suicide per year.1 Mental 
illnesses, particularly major depressive disorder, (MDD) are 
the main risk factor for suicide. Although several factors 
including personality and cultural and ethnic background 
may exert influence on suicidality of depressed patients, 
neurobiological factors involved in suicidal ideation and be-
havior has received considerable attention. Several studies 
have documented different biological changes in subgroups 
of individuals with MDD and suicidal behavior,2 including 
serotonergic and noradrenergic system abnormalities. 
Hypothalamus-pituitary-adrenal (HPA) axis dysfunction has 
also been reported. 
A growing body of evidence has indicated the pres-
ence of a longstanding pro-inflammatory state in MDD. 
Increases in inflammatory mediators such as cytokines were 
extensively shown in MDD, with interleukin-6 (IL-6), tumor 
necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) be-
ing the most commonly associated with MDD.3-5 The causes 
for this pro-inflammatory state are largely unknown, 
although both genetic and environmental factors have 
been proposed as relevant.6 Chemokines, cytokines with 
chemoattractive properties, have received less attention 
regarding their role in MDD. Nevertheless, these inflam-
matory mediators may be of particular interest in these 
patients, given their effect on the amplification of inflam-
matory response, possibly resulting in increased neuronal 
and glial death.3,7-9 For instance, peripheral chemokine 
levels seem to be altered in neurodegenerative disorders, 
such as multiple sclerosis10 and Alzheimer’s disease11,12 and 
in neuropsychiatric disorders such as schizophrenia13,14 
and bipolar disorder.15 To date, more than 50 chemokines 
and approximately 20 chemokine receptors, particularly 
G-protein-coupled receptors,16 have been identified. The 
two largest families of chemokines, CCL and CXCL, attract 
mononuclear cells to sites of chronic inflammation. The 
binding of a chemokine to its receptor activates signal-
ing cascades that lead to cell shape rearrangement and 
movement,17 namely chemokine (C-C motif) ligand 11 
(Eotaxin/CCL11).18 Activation of these signaling pathways 
results in increased calcium concentrations and activa-
tion of mitogen-activated protein kinases, and also has a 
role in synaptic plasticity.16 For instance, CCL and CXCL 
chemokines have been shown to help in the prevention 
of neuronal apoptosis.19,20 Monocyte chemotactic pro-
tein-1 (MCP-1/CCL2) and regulated-on-activation normal 
T cell expressed and secreted (RANTES/CCL5) protein are 
important mediators of the immune and inflammatory 
responses.21
Studies exploring differences in inflammatory media-
tors across subgroups of depressive patients are scarce. A 
recent report indicated differences in cytokine concentra-
tions among suicide attempters compared to non-suicidal 
depressed patients and healthy controls.22 Suicide attempters 
have increased levels of IL-6 and TNF-α as well as decreased 
levels of IL-2 concentrations. Unfortunately there are very 
few studies investigating the role of chemokines in major 
depression and suicide.23 
Because understanding the inflammatory mechanisms 
involved in MDD and suicide may potentially open new treat-
ment possibilities, the aim of this study was to investigate 
chemokine differences between MDD individuals with and 
without suicidal ideation, in order to propose novel markers 
of suicidal ideation in MDD.
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Methods
Thirty patients with recurrent MDD were recruited from a 
specialized outpatient clinic (Mood Disorders Program) at 
Hospital Presidente Vargas, Porto Alegre, Brazil. Psychiatric 
diagnosis was based on application of the Structured Clinical 
Interview for DSM-IV-Axis I Disorders (SCID-I). Depression 
severity was evaluated by Beck Depression Inventory (BDI). 
Suicidal ideation (SI) was assessed by SCID-I (“Over the last 
month: Have you wished you were dead?”; “Have you wanted 
to harm yourself?”; “Have you thought of committing sui-
cide?”; and “Have you planned how to commit suicide?”) and 
BDI (“I have thoughts about committing suicide but I would 
not carry them out”; “I have definite plans about commit-
ting suicide”; “I would kill myself if I could”). Outpatients 
were classified according to whether they reported in both 
instruments to have (n = 18) or have not (n = 12) suicidal 
ideation. All patients had been using a stable dosage of 
antidepressant monotherapy at least for 3 months and were 
free of other medications for 4 weeks before blood collec-
tion. Exclusion criteria were: axis I comorbities; severe or 
unstable clinical illness or illness associated with reports on 
abnormal immunological parameters; body mass index (BMI) 
above 30 kg/m2; neurological disorder; psychotic symptoms 
or any psychoactive substance used in past 30 days (except 
nicotine, caffeine, and antidepressants); current use of 
corticosteroids or nonsteroidal anti-inflammatory drugs; and 
acetylsalicylic acid or immunosuppressives. 
Sixteen healthy volunteers were matched by age, social 
status, and BMI in MDD patients. Healthy control group was 
screened for psychiatric disorders using the non-patient 
version of SCID-I. Subjects included in the study were not 
using any medication, and their first-degree relatives had 
no history of major psychiatric disorders, dementia, mental 
retardation, cancer, or tumor. Exclusion criteria for healthy 
subjects were the same as those used in the selection of MDD 
patients. All participants had their socioeconomic status (SES) 
rated by the Hollingshead Index based on marital status, 
gender, occupation, and education.24
Five milliliters of blood were collected from each subject 
by venipuncture in EDTA tubes. Samples were immediately 
centrifuged at 3000g for 5 min, and plasma was kept frozen 
at -80°C until assayed. Plasma concentration of chemokines 
was determined using sandwich ELISA kits, following the 
manufacturer’s protocol (R&D Systems, Minneapolis, MN, 
USA). All samples were assayed in duplicate. Assay detection 
limit was 5 pg/mL.
Statistics
Descriptive analyses included assessment of the distribu-
tion of all variables; data are presented as means and 
percentages. Demographic and clinical characteristics were 
analyzed using the χ2-test and analysis of variance (ANOVA), 
as indicated. Chemokine levels showed a non-parametric 
distribution and were analyzed after log transformation. 
Multivariate analysis of covariance (MANCOVA) was employed 
to compare mean differences between groups adjusting for 
those variables with significant differences in univariate 
ANOVAs. Statistical significance was set at p < 0.05. Statistical 
analyses were performed using the Statistical Package for 
the Social Sciences (SPSS) version 17.0 (SPSS Inc., Chicago, 
IL, USA).
Results
Demographic and clinical characteristics of the sample 
(n = 49) are presented in Table 1. Both groups were homoge-
neous in terms of age, socioeconomic status, and education. 
All patients reported high scores of BDI (mean, SD, n; 29.75, 
10.55, 28) presenting 11.5 years of illness duration (SD 5.58) 
and no medical comorbities. As expected, outpatients with 
MDD and SI presented higher scores of depression severity. 
There were no differences between MDD with SI versus MDD 
without SI groups regarding the use of tricyclics (50% vs. 
41.7%, p = 0.71), selective serotonin reuptake inhibitors (39% 
vs. 50%, p = 0.72), or other antidepressants use (11.1% vs. 
8.3%, p = 0.99. The type of antidepressant had no influence 
on CCL2, CCL5, and CCL11 plasma levels (F = 2.52, p = 0.743) 
among MDD patients.
Multivariable analysis of covariance adjusted for age and 
BMI showed that MDD with SI presented lower levels of MCP-1/
CCL2 and RANTES/CCL5 compared with MDD without SI and 
controls. Higher levels of Eotaxin/CCL11 in MDD with SI and 
MDD without SI were identified when compared to healthy 
controls. All differences remained significant after adjusting 
for depression severity (Figure 1). Assumptions for MANCOVA 
were tested and met. Independence was met through the study 
design; multivariate normality and linearity were assessed 
Table 1 Clinical and demographic characteristics of the sample and results of chemokine measurements
Healthy Control (n = 16) Non-suicidal Ideation (n = 12) Suicidal Ideation (n = 18) p Post hoc test c
Age (years) 38.12 (3.87) 37.75 (9.45) 40.17 (8.25) 0.643 HC = NSI = SI
Education (years) 8.56 (2.55) 8.58 (4.4) 7.83 (3.51) 0.783 HC = NSI = SI
BMI a 25.80 (1.73) 24.97 (2.42) 26.28 (2.10) 0.27 HC = NSI = SI
BDI b 5.12 (3.87) 20.83 (9.36) 33.61 (9.51) < 0.0001 HC < NSI < SI
CCL2 (pg/mL) 536.74 (184.12) 523.94 (212.88) 353.97 (92.60) 0.004 HC, NSI > SI d
CCL5 (pg/mL) 14,179.42 (452.92) 12,297.84 (1,703.47) 9,823.13 (2,786.36) < 0.0001 HC > NSI > SI d
CCL11 (pg/mL) 429.03 (272.85) 595.64 (183.11) 603.76 (281.21) 0.109 HC = NSI = SI
Data are presented as mean (SD).
a Body Mass Index; b Beck Depression Inventory; c Gabriel’s procedure was used for post hoc comparisons; d Same results when controlling depression 
severity as a covariate (MANCOVA).
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by examining bivariate scatter plots; and the Box’s Test of 
Equality of Covariance Matrices was used to test the null hy-
pothesis, which showed that covariance matrices of dependent 
variables were equal across all groups (F = 1.40; p = 0.33).
Discussion
The results of this study indicate the existence of differences 
in chemokine levels between recurrent MDD and healthy 
controls. In addition, the presence of SI affected significantly 
the chemokine profile. MDD with SI presented lower levels 
of MCP-1/CCL2 and RANTES/CCL5 in comparison with MDD 
without SI and healthy controls.
Although inflammatory changes have been associated with 
mood disorders and schizophrenia, results from different 
studies are frequently inconsistent and heterogeneous.14,15,25 
Chemokine levels have been an understudied topic in psychi-
atric disorders. Similarly, possible differences in these media-
tors between individuals with and without suicidal ideation 
are also an understudied issue. The few studies regarding 
inflammatory activity and suicide26,27 have divergent results. 
Comparing MDD individuals with healthy volunteers, Lehto 
et al.23 found that MDD was associated with lower levels of 
chemokines MCP-1/CCL2, MIP-1β, and IL-8/CXCL8. In line 
with these results, our preliminary findings showed reduced 
MCP-1/CCL2 levels in severe chronic MDD patients reporting 
suicidal ideation. 
There is some recent evidence that non-suicidal and 
suicidal patients with MDD may have distinct immunologi-
cal profiles. It was recently shown that suicidal depression 
had a Th1/Th2 imbalance with lower interleukin-2 (IL-2).28 
Th1-type cytokines tend to produce the proinflammatory 
responses. Excessive proinflammatory responses can lead 
to uncontrolled tissue damage, thus a mechanism to coun-
teract this damage is necessary. In excess, Th2 responses 
will counteract the Th1 mediated microbicidal action. The 
optimal scenario seem to be that humans should produce a 
well balanced Th1 and Th2 response, suited to the immune 
challenge (Berger 2000). These results of our study corrobo-
rate the hypothesis of a disruption in Th1/Th2 balance in MDD 
with suicidal ideation. Low plasma concentrations of MCP-1 
and RANTES in MDD patients with suicidal ideation could be 
an important factor in the pathogenesis of this disorder, as 
these proteins have either a protective or detrimental role, 
depending on the inflammatory stimulus, cell type, or disease 
state.29,30 Prior studies have shown that the inhibition of MCP-
1 activity, using neutralizing antibodies or in knock-out mice 
lacking MCP-1, resulted in a dysregulation of the cytokine 
balance and increased mortality.31 In addition, our findings 
are in line with other report that found activation of inflam-
matory response in Cerebrospinal Fluid (CSF) of individuals 
who committed suicide.32
The results of the present study must be interpreted in 
light of its limitations. One of them is the small sample size, 
therefore, this data should be considered preliminary. The 
participants included in MDD groups were taking antidepres-
sants, and we could not rule out that our results may be due 
to possible anti-inflammatory effects of such medications on 
chemokines levels. In addition, the authors did not exclude 
nicotine users from the sample, which can be an important 
confounding factor for chemokine analyses. Because only 
female participants were included, other studies must be 
conducted including males.
Even considering the limitations, our results demonstrate 
for the first time that suicidal patients possibly display a dis-
tinct chemokine profile compared to non-suicidal depressed 
patients. If these results were confirmed in future researches, 
chemokine measurements may potentially be converted into 
a biomarker for suicidality in individuals with MDD.
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Figure 1 Multivariable analysis of covariance adjusted for age and BMI.
Multivariable analysis of covariance adjusted for age and BMI showed that MDD with SI (n = 18) presented lower levels of MCP-1/CCL2 (M = 354.51 pg/mL, 
± 39.75; F = 2.96, p = 0.031) and RANTES/CCL5 (M = 9,823.13 pg/mL, ± 2,786.36; F = 11.91, p < 0.001) in comparison with MDD without SI (n = 12) (MCP-1, 
M = 504.08 pg/mL, ± 50.89; RANTES, M = 12,384.56 pg/mL, ± 1,758.61) and controls (n = 16) (MCP-1, M = 537.24 pg/mL, ± 41.52; RANTES, M = 14,179.42 pg/mL, 
± 452.92).
Higher levels of Eotaxin/CCL11 in MDD with SI (M = 603.76 pg/mL, ± 281.21) and MDD without SI (M = 591.92 pg/mL, ± 191.58) were identified when compared 
to healthy participants (M = 429.74 pg/mL, ± 272.85) (F = 2,77; p = 0.04). All differences remained significant after adjusting for depression severity.
There were no statistically significant difference between MDD without SI and healthy controls in MCP-1 and RANTES levels. There were no statistically 
significant differences between MDD with and without SI in Eotaxin levels.
* p < 0.05 by Tukey's HSD.
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